Chronic obstructive pulmonary disease (COPD) is a major public health problem that is projected to rank fifth worldwide in terms of disease burden and third in terms of mortality. Chronic bronchitis is associated with multiple clinical consequences, including hastening lung function decline, increasing risk of exacerbations, reducing health-related quality of life, and possibly raising all-cause mortality. Recent data suggest greater elucidation on the risk factors, radiologic characteristics, and treatment regimens. Our goal was to review the literature on chronic bronchitis that has been published in the past few years.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a major public health problem that is projected to rank fifth worldwide in terms of disease burden and third in terms of mortality [1] . Chronic bronchitis is a common clinical phenotype in COPD and is classically defined as chronic cough and sputum production for 3 months a year, for 2 consecutive years [2] , but many studies have used different definitions to define it. No matter how it is described, it is clear that chronic bronchitis is associated with multiple clinical consequences, including hastening lung function decline, increasing risk of exacerbations, reducing health-related quality of life, and possibly raising all-cause mortality [3] [4] [5] [6] [7] [8] . Despite its clinical consequences, the literature regarding its pathophysiology, radiologic characteristics, and clinical phenotype has been sparse. Recently, however, there has been a growing body of literature that more carefully describes environmental risk factors, epidemiology, and genetics associated with chronic bronchitis. In addition, as computed tomography (CT) technology continues to improve, the radiologic phenotype associated with chronic bronchitis is better understood. Herein, we will describe our current understanding of chronic bronchitis in COPD, with an emphasis on recent literature. surprisingly 31.2% are between the ages of 18 and 44 years.
The numbers affected by chronic bronchitis dramatically increase with smoking. Pelkonen et al. [4] followed 1711 Finnish men in rural communities for 30 years and found the incidence of chronic bronchitis was 42% in continuous smokers, 26% in ex-smokers, and 22% in never-smokers. In a recent cross-sectional study of over 5000 adult current or ex-smokers with over a 10-pack-year history, the prevalence of chronic bronchitis, using the classic definition, was a striking 34.6% [20 & ]. The prevalence of chronic bronchitis is higher in COPD patients, affecting 14-74% of all COPD patients [24] [25] [26] 27 && ]. Chronic bronchitis seems to affect whites more than blacks, but the majority of studies have been composed of mostly whites [4, 11, 14, 19, 28] . A recent study of non-Hispanic whites and blacks found that COPD patients were more likely to be white than black, but the differences in racial distribution between those with and without chronic bronchitis were small [27 && ]. Sex has also been a matter of debate. Many studies have found that chronic bronchitis affects men more than women [26,27 && ,29,30] . However, according to the 2013 American Lung Association study, the prevalence rates of chronic bronchitis in women were nearly twice that in men (59.7 ]. A 10-year study of 21 130 Danish patients showed that the cumulative prevalence of chronic mucus secretion was 10.7% in women vs. 8.7% in men [19] . The reasons for the higher prevalence of chronic bronchitis in women compared to that in men are unclear, but may be due to hormonal influences, sex differences in symptom reporting, and sex diagnostic bias; for example, in the European Respiratory Society Study on Chronic Obstructive Pulmonary Disease (EUROSCOP) study, women reported more dyspnea and cough, but less phlegm symptoms than men [31] .
Recent evidence has suggested that chronic bronchitis may be underdiagnosed, likely related to the various definitions used for chronic bronchitis. Using a definition of chronic phlegm alone for most days, 3 months a year, for 2 years, the Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO) study estimated a chronic bronchitis prevalence of 14.4 and 6.2% in those with and without COPD, respectively [26] . When using the classic definition, however, the prevalence fell to 7.4 and 2.5%, respectively. In the Genetic Epidemiology of COPD (COPDGene) study [32] , the prevalence of chronic bronchitis was 26.2% in Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1-4 patients using the classic definition, but was 39% when using a novel definition of cough and phlegm using the Saint George's Respiratory Questionnaire (unpublished data). A large epidemiologic survey of the French general population showed a chronic bronchitis prevalence of 3.5%, but only 28.6% of these patients reported a history of respiratory disease [33] . These data highlight the need to ask the appropriate questions when interviewing patients at risk for chronic bronchitis and the need of a more uniform definition across studies.
RISK FACTORS
The primary risk factor of chronic bronchitis is smoking. As mentioned earlier, the cumulative 30-year incidence of chronic bronchitis in current smokers is 42% [4] . A 2011 meta-analysis has found that ever smoking conferred a 2.69 [95% confidence interval (CI) 2.50-2.90], and current smoking was associated with a relative risk of 3.41 (95% CI 3.13-3.72) [34] . More recent literature has supported the increased risk of chronic bronchitis conferred by smoking [27 && ,35 && ]. Sumner et al. [36] objectively measured cough in those with and without COPD with 24-h cough monitoring and found that the greatest cough frequency was in COPD current smokers, followed by COPD exsmokers and healthy current smokers. In addition, in this study, reported sputum production, smoking history, and current smoking predicted cough frequency. However, chronic bronchitis has been described in 4-22% of never-smokers [4, 16] , suggesting that other risk factors may exist. Interestingly, two cross-sectional studies showed stable rates of chronic bronchitis of 12.5-12.6% in young adults, even though the rates of smoking decreased from 33.6 to 26.9% [37] . Recent literature has highlighted that occupational exposures, biomass fuels, dusts, and chemical fumes place individuals at risk for developing chronic bronchitis.
Although a significant body of literature exists that ties occupational exposures with worsening asthma control and bronchial hyper-responsiveness, the link between chronic bronchitis and occupational exposures is just beginning to emerge. A study involving 338 hospitalized COPD patients in nine Spanish hospitals found that high exposure to gases or fumes was associated with chronic bronchitis symptoms [38] . Dijkstra et al. [35 && ] found that exposures to mineral dusts, and gases and fumes was associated with an odds ratio (OR) of 1.38 and 2.19, respectively, in 8529 patients without COPD. There were also significant interactions found between the presence of COPD and exposures to gases, fumes, and aromatic solvents in this cohort, comprised of an additional 1479 patients with COPD diagnosed by spirometry. Exposure to both dusts and fumes was associated with an increased risk of chronic cough and chronic phlegm (ORs 1.83 and 1.82, respectively) after adjustment for demographic factors and smoking in the COPDGene cohort, a study that involved more than 9600 patients with and without COPD [39 && ]. These associations show that, regardless of the presence of airflow obstruction, significant gas and fume exposure can result in chronic cough and sputum production. The specific gases or fumes, as well as the amount of exposure necessary, remain unclear and deserve further investigation.
In the past decade, it has become apparent that exposure to biomass fuels, such as wood, dung, and crop residues, is a significant risk factor for COPD. Biomass smoke exposure predominantly affects women in rural areas who use these fuels for cooking. With the increasing understanding of the risk of developing COPD conferred by biomass smoke, it is apparent that it also increases risk for developing chronic bronchitis. Compared to COPD due to tobacco smoking, those with COPD related to biomass smoke exposure have more cough, phlegm symptoms, and air trapping on CT scan [40 && ]. Two recent studies comparing radiologic phenotypes between tobacco smoke-exposed and biomass smoke-exposed patients matched for lung function found that the biomass group had more air trapping or peribronchial thickening and less emphysema than the tobacco group, suggesting an airway-predominant phenotype [41, 42] . In another study of wood smoke-exposed women with COPD, the most common findings on high resolution computed tomography (HRCT) scans were bronchial wall thickening, bronchiectasis, mosaic perfusion pattern, parenchymal bands, and tree-in-bud opacities [43] . These radiologic findings suggest a bronchitic clinical phenotype, as chronic bronchitis is associated with greater airway wall thickening and gas trapping on CT scan [27 && ]. Air pollution is another risk factor for worsening of chronic bronchitis symptoms and exacerbations. Ozone studies have shown diminished lung function, reduced exercise capacity, and lung inflammation at levels at or below the National Ambient Air Quality Standards of air quality [44] . To make matters worse, ambient ozone levels are expected to increase in the upcoming decades [45] . A study of over ten years of ambient ozone levels found that increased ozone levels were associated with greater emergency department visits for chronic bronchitis [46 & ]. In a meta-analysis of 23 studies examining allcause mortality associated with outdoor fine particulate matter [particles with a median diameter <2.5 mm (PM 2.5 )] air pollution, a 10 mg/ml increment in PM 2.5 was associated with an increase in the risk of death, particularly respiratory causes of death (1.51%, 95% CI 1.01-2.01) [47 && ]. There is also supportive literature that air pollution increases systemic biomarkers of inflammation in COPD patients, particularly interleukin (IL)-8, C-reactive protein, fibrinogen, and hepatocyte growth factor [48] . Systemic levels of C-reactive protein and fibrinogen have been shown in univariate analysis to be greater in COPD patients with chronic bronchitis in the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) [49] . Other studies, however, have not been as supportive of the association between air pollution with chronic bronchitis. A meta-analysis of five cross-sectional studies in Europe found no statistically significant association between any air pollutant and chronic bronchitis except in never-smokers (OR 1.31 for PM coarse ) [50 & ].
Recently, more data have emerged linking the chronic bronchitis phenotype with upper airway symptoms. An analysis of two large epidemiologic cross-sectional surveys of young adults conducted at different times (1998/2000 and 2007/2010) found that the likelihood of having chronic bronchitis was significantly higher in patients with allergic rhinitis [37] . This study also revealed that although the prevalence of chronic bronchitis remained stable, the rates of current smoking dropped over the time span between the two surveys and the prevalence of allergic rhinitis increased, strengthening the association between upper airway and lower airway symptoms. In an analysis of the National Health and Nutrition Survey III (NHANES III), the presence of self-reported doctor-diagnosed hay fever or allergic upper respiratory symptoms (21.4% of 1381 patients) was independently associated with chronic cough and phlegm [51 & ]. Exacerbation rates were greater in those with an allergic phenotype compared to those without it. In the COPDGene cohort, those with COPD and chronic bronchitis (24.5% of 2703 patients) were more likely to have allergic nasal and ocular symptoms and exacerbation frequency compared to COPD patients without chronic bronchitis [27 && ].
GENETICS
As chronic bronchitis exists in those without airflow obstruction, and not everyone with COPD develops chronic bronchitis, it is clear that predisposing factors in combination with exposures lead to chronic bronchitis. Recent data have revealed possible genetic predispositions. In a population-based study of 13 649 twins, from the Danish Twin Registry, chronic bronchitis showed moderate familial aggregation, especially in women [52] . Genome-wide association analysis in the Netherlands of chronic mucus hypersecretion showed a strong association with a single-nucleotide polymorphism (SNP) on chromosome 3 [53] . A simultaneous analysis of three different cohorts -COPDGene (non-Hispanic whites and blacks), GenKOLS (Bergen, Norway), and the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) -found a new genome-wide locus of chromosome 11p15.5 in COPD patients with chronic bronchitis compared to smoking controls [54 & ]. As the understanding of COPD genetics increases, perhaps we will be able to elucidate the gene-environment interactions responsible for the development of chronic bronchitis.
RADIOLOGIC FEATURES
Chronic bronchitis is associated with greater airway disease on CT scan. One of the first studies that compared 20 COPD patients with chronic bronchitis and 22 COPD patients without chronic bronchitis found significantly higher bronchial wall percentage areas and thickness-to-diameter ratios in those with chronic bronchitis compared to patients without chronic bronchitis [55] . More recent studies have corroborated these initial findings in different cohorts and using different quantitative techniques. A recent study showed that sputum purulence in combination with lung function measures strongly predicted airway wall thickness of 10 mm airways (Pi10) in 373 COPD patients [56] . In the COPDGene study, which involved over 2700 COPD patients with complete radiographic analysis and pertinent clinical histories, airway wall thickness in combination with lung function, smoking history, allergic symptoms, and gastroesophageal reflux was predictive of chronic bronchitis in a multivariate model [27 && ]. Table 2 summarizes the current data regarding the outcomes associated with chronic bronchitis.
CLINICAL FEATURES
Multiple studies have shown that chronic bronchitis accelerates lung function decline [3, 56] , worsens health-related quality of life [25-27 && ] , may increase mortality [4, 5, 29, 60] , and increases the risk of exacerbations [3, 24, 26] . Some literature on exacerbations leaves the link with exacerbations and chronic bronchitis debatable. In the ECLIPSE study, chronic bronchitis defined as chronic cough was a significant predictor of exacerbations, but only on univariate analysis [65] . Another study of smokers without spirometric evidence of COPD found chronic bronchitis to again be a significant risk factor for respiratory exacerbations, but only on univariate analysis [66] .
Recent data, however, have more firmly established the link between chronic bronchitis and exacerbations. A multicenter cross-sectional study of 975 GOLD 2-4 COPD patients, where the prevalence of chronic bronchitis was 64%, found that the chronic bronchitis group had more exacerbations (2.08 AE 2.78 vs. 1.05 AE 1.71 exacerbations/patient/ year; P < 0.0001), a higher percentage of patients with frequent exacerbations (37.3 vs. 14.2%; P < 0.0001), more hospital admissions due to COPD (0.28 AE 0.75 vs. 0.15 AE 0.43 hospitalizations/patient/ year; P ¼ 0.0027), and more all-cause hospitalizations (0.52 AE 0.91 vs. 0.38 AE 0.83 hospitalizations/ patient/year; P ¼ 0.0185) [59] . An analysis of the COPDGene study (cross-sectional, multicenter) of GOLD 1-4 patients found similar trends in total exacerbation frequency (0.96 AE 1.46 vs. 0.52 AE 1.04 exacerbations in the past year; P < 0.0001) and history of severe exacerbations (24.2 vs. 15.2%; P < 0.0001) [27 && ]. An analysis of the GOLD 0 patients from the COPDGene study also found that those with chronic bronchitis (12.2% of 4880 patients) had an increased rate of respiratory exacerbations [67] . In the long-term follow-up of 8246 patients in the COPDGene study, chronic bronchitis was independently associated with exacerbation risk in all patients (hazard ratio 1.15, 95% CI 1.03-1.28), including GOLD 0 and GOLD U (undefined, indicating smokers at risk for COPD with restrictive lung disease on spirometry) [68] . Similar trends were seen in the COPD Clinical Research Network Azithromycin trial (MACRO) and the SPIROMICS cohorts [49, 69] . Using a novel definition of severe chronic bronchitis, defined as chronic cough, phlegm, and chest trouble, we found that severe chronic bronchitis was associated with increased mortality and all-cause hospitalizations in the National Emphysema Treatment Trial cohort [70 & ].
IMPLICATIONS FOR TREATMENT
Treatment for COPD and chronic bronchitis is multifold and includes both pharmacologic and nonpharmacologic strategies. Please refer to a recent review for more extensive discussion on this topic [71 && ]. Exacerbation rates remain high in those with chronic bronchitis, despite treatment with COPD maintenance medications [72] . Therefore, the primary focus in recent research has been on reducing exacerbations in this high-risk population.
Macrolide antibiotics have been shown to have anti-inflammatory properties and have been used to decrease COPD exacerbations. Independent of their antibiotic properties, macrolides have been shown to reduce neutrophil elastase-induced mucus stasis, suggesting benefit in chronic bronchitis [73] . The effect of chronic macrolide therapy on COPD exacerbations was assessed in 109 patients randomly assigned to receive erythromycin 250 mg or placebo twice daily for 1 year [74] . The erythromycin group had significantly fewer exacerbations than the placebo group. A recent large, prospective, placebocontrolled, randomized trial on the use of azithromycin (250 mg daily for 1 year) to prevent acute exacerbations of COPD showed that azithromycin was associated with a significant decrease in exacerbation frequency and an improvement in health related quality of life (HRQoL) [75] . There was, however, no additional benefit conferred to those with chronic bronchitis [76] . What future studies with macrolides will show in those with chronic bronchitis remains to be determined. Phosphodiesterase-4 inhibitors, particularly roflumilast, may be beneficial in the treatment of chronic bronchitis. Acquired dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) in airway epithelial cells can delay mucociliary transport, and has been associated with chronic bronchitis [77 & ]. Moreover, roflumilast activates CFTR-mediated anion transport [78] , which may be at least one mechanism of its benefit in chronic bronchitis. In two 24-week trials, 933 patients with moderate to severe COPD were randomly assigned to roflumilast and salmeterol, or salmeterol alone, and 743 patients were randomly assigned to roflumilast and tiotropium or tiotropium alone [79] . The overwhelming majority of patients (78-100%) endorsed chronic cough and sputum production. In both trials, roflumilast significantly reduced exacerbation rate. Thus, as chronic bronchitis increases risk for exacerbation, roflumilast may play a preferential role in preventing exacerbations in patients with chronic bronchitis and COPD. GOLD currently recommends roflumilast for those with chronic bronchitis and in those with frequent exacerbations as second-line therapy [1] .
As oxidative stress is crucial to the pathogenesis of COPD, antioxidant therapy may be of benefit in COPD treatment. The two most extensively studied antioxidant medications for COPD are N-acetylcysteine (NAC) and carbocysteine. Unfortunately, the two largest trials showed either no or weak reductions in exacerbations in the long-term follow-up [80, 81] . A more recent study -High-Dose N-Acetylcysteine in Stable COPD (HIACE) studyenrolled 120 patients with stable COPD from one center and randomized them to receive NAC 600 mg twice daily or placebo for 1 year [82] . The NAC group had a statistically significant increase in small airways function as measured by forced expiratory flow (FEF) 25-75 compared to placebo, but there was no difference in exacerbation frequency. A larger multicenter randomized controlled trial randomized 1006 patients to the same NAC regimen or placebo and found significant reductions in exacerbation frequency (risk ratio 0.78, 95% CI 0.67-0.90) [83 && ].
CONCLUSION
The recent data on chronic bronchitis have shed more light on the epidemiology, risk factors, radiologic features, genetic influences, and therapeutic strategies. This should influence the clinician to maintain a higher index of suspicion for chronic bronchitis, given the recent growing body of literature on risk factors and phenotype. However, more study is needed to determine why some smokers develop chronic bronchitis and others do not and on how smoking cessation affects its natural history.
In addition, more research on the pathophysiology of this disease process will help development of better therapies that directly target chronic bronchitis in order to improve quality of life, decrease exacerbations, and reduce mortality. 
